Optimi Health Corp. has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, strengthening its position as a pioneering force in the psychedelic research and formulation space.

Demonstrating its commitment to innovation and research, Optimi has cultivated these new Psilocybin-containing mushroom strains with the aim that they will play a pivotal role in the development of psilocybin extracts and novel drug candidates. Optimi also announces the advancement of its full spectrum, GMP extract quality program. The Company has successfully completed process validation for the natural psilocybin drug candidate, and the stability testing according to ICH guidelines is ongoing.

With over three months of accelerated data, Optimi can confirm the product is able to maintain potency and other quality attributes for the duration of clinical trials. While Optimi continues to develop its product offerings, it remains focused on fulfilling supply orders, conducting tests, and analyzing the recent milestone harvest. The company announced the availability of GMP Psilocybin API for encapsulation into standardized dosages or for sale to other groups as a raw material for their formulations.

This marks a significant step in expanding the company's reach and impact within the psychedelic research community.